Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

Tolerability, Safety, and Pharmacokinetics of Repeated Sublingual Doses of Lobeline

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00519259

Enrollment

Registered

2007-08-22

Start date

2006-02-28

Completion date

Unknown

Last updated

2017-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine Dependence

Brief summary

The purpose of this study is to assess safety and pharmacokinetics of sublingual lobeline in healthy normal volunteers.

Interventions

DRUGLobeline

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Must be able to provide written informed consent * Must have a body mass index between 18 and 30 * Have no medical contraindications as determined by medical history, physical exam, ECG, hematology and blood chemistry profile, and urinalysis * Must have a negative drug test at screening and admission * If female of child bearing potential, must agree to use birth control

Exclusion criteria

* Please contact the site for more information

Design outcomes

Primary

Measure	Time frame
Tolerability	—

Secondary

Measure	Time frame
Safety	—
Pharmacokinetic parameters	—
Cardiovascular responses	—
Psychological effects of lobeline	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026